Orexo is a fully integrated specialty pharmaceutical company which has developed four products from idea to patient.
Products approved worldwide
Our drug delivery technologies improve pharmaceuticals
Partnerships are critical to our success
We will be recognized for the added value our products bring to patients and societies
Orexo’s share is listed on Nasdaq Stockholm Mid Cap and available as American Depository Receipts (ADRs) on OTCQX in the US.
Follow Orexo in social media
Rapport om epidemin kring opioidberoende iUSA. 2016 dog ca 60 000 amerikaner av en överdos relaterat till opioider.
Överdoslarm ökar kraftigt i USA: ”Det är en epidemi” https://t.co/Y2zNLfSBPR via @SvD
#Orexo Q3 report will get released Oct. 19. The same day at 2 pm, Nikolaj Sørensen, CEO, and Henrik Juuel, CFO, wi… https://t.co/3d9xnquCiB